Women may be at greater risk than men for experiencing hyperprogression as a response to cancer treatment with immune checkpoint inhibitors, say researchers.
Hisham Mehanna describes the results of the De-ESCALaTE HPV trial comparing cetuximab versus cisplatin for the treatment of low-risk oropharyngeal cancer patients undergoing radiotherapy (5:43).
Barbara Burtness talks through the results of the KEYNOTE-048 trial comparing pembrolizumab alone or with chemotherapy versus the EXTREME regimen for patients with recurrent or metastatic head and neck cancer (5:10).
The efficacy of programmed cell death protein 1 inhibition with nivolumab may be amplified by vaccination against human papillomavirus-16 in patients with incurable HPV-16–positive cancer, phase II study data suggest.
Human papillomavirus positivity is associated with improved survival in patients with head and neck cancer at four of six subsites in the upper aerodigestive tract, US study findings indicate.